The use of prophylactic eye drops during high-dose cytosine arabinoside therapy.
An ocular toxic reaction presenting as conjunctivitis or keratitis develops in a significant number of patients who are treated with high-dose cytosine arabinoside (ara-C). Although eye drops containing glucocorticoid reportedly decrease the incidence, they do not totally eliminate this side effect. In comparing this technique with artificial tears, both were found to be equally effective. The primary mechanism by which eye drops decrease ocular toxic reactions associated with high-dose ara-C is presumably due to dilution of intraocular concentrations of ara-C.
Higa
G M
GM
Department of Pharmacy, Medicine (Hematology-Oncology) and Nursing, Duke University Medical Center, Durham, North Carolina.
Gockerman
J P
JP
Hunt
A L
AL
Jones
M R
MR
Horne
B J
BJ
D000328:Adult; D000368:Aged; D003231:Conjunctivitis / Q000139:chemically induced / Q000517:prevention & control*; D003561:Cytarabine / Q000009:adverse effects*; D003907:Dexamethasone / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007634:Keratitis / Q000139:chemically induced / Q000517:prevention & control*; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D011239:Prednisolone / Q000031:analogs & derivatives* / Q000627:therapeutic use
D009883:Ophthalmic Solutions; D003561:Cytarabine; C009022:prednisolone phosphate; D003907:Dexamethasone; D011239:Prednisolone